Repatha Medicare Part D Coverage: What You Will Actually Pay in 2026

What Is Repatha and Why Does It Cost So Much?

Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein the liver uses to clear LDL receptors from its surface. By blocking PCSK9, each dose increases the number of LDL receptors available to pull cholesterol out of the blood. The FDA approved Repatha in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and clinical atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL lowering [1]. The original list price exceeded $14,000 per year, though Amgen reduced it by roughly 60% in 2018 after negotiations with payers [2].

Even after the price cut, the wholesale acquisition cost sits near $5,850 annually. That figure still places Repatha in the specialty-drug category for most Part D sponsors, meaning patients land on Tier 5 formularies with coinsurance rates of 25% to 33% before reaching the catastrophic phase [3]. Manufacturing cost is high because evolocumab is produced in Chinese hamster ovary (CHO) cell bioreactors, purified through multiple chromatography steps, and filled into single-use autoinjectors or prefilled syringes, a process that cannot be replicated with simple generic small-molecule synthesis [4].

How Medicare Part D Covers Repatha in 2026

Part D plans are required to cover "all or substantially all" drugs in six protected classes, but PCSK9 inhibitors are not among them. Each plan therefore sets its own coverage terms. In practice, the vast majority of stand-alone Part D plans (PDPs) and Medicare Advantage Prescription Drug plans (MA-PDs) do list evolocumab, but almost always with prior authorization and step-therapy requirements [5].

The typical prior authorization asks the prescriber to document:

1. A diagnosis of ASCVD, HeFH, or HoFH confirmed by clinical criteria or genetic testing.
2. A fasting LDL-C above the patient's risk-appropriate goal despite maximally tolerated statin therapy.
3. Trial and failure (or documented intolerance) of ezetimibe added to the statin [6].

Some plans also require a trial of bempedoic acid (Nexletol) before approving a PCSK9 inhibitor. Denials can be appealed; CMS data from 2024 showed that roughly 48% of initial Part D prior-authorization denials for PCSK9 inhibitors were overturned on first-level appeal [7].

A 2019 analysis in JAMA Cardiology found that among patients with an ASCVD indication, only 30.4% of new PCSK9 inhibitor prescriptions were filled within 90 days of being written, largely because of insurer-imposed access barriers [8].

The $2,000 Out-of-Pocket Cap: What It Means for Repatha Users

The Inflation Reduction Act (IRA) restructured Part D cost-sharing beginning in 2025. The annual out-of-pocket maximum is now $2,000, replacing the old catastrophic-phase structure in which beneficiaries paid 5% of drug costs indefinitely [9]. For a drug with a retail price near $580 per fill, patients previously could accumulate $3,000 or more in annual out-of-pocket spending before catastrophic coverage began. Under the new cap, once a patient reaches $2 to 000 in true out-of-pocket costs (TrOOP), Part D pays 100% for the remainder of the year.

CMS also introduced the Medicare Prescription Payment Plan, which lets enrollees spread their out-of-pocket costs across monthly installments rather than paying large sums at the pharmacy counter [10]. This is not a discount; the total remains $2,000 or less, but it eliminates the shock of a $400+ copay in January.

Step-by-Step: How to Get Repatha Covered Under Your Part D Plan

Start by confirming that your specific PDP or MA-PD lists evolocumab on its formulary. CMS maintains a searchable formulary finder at Medicare.gov [11]. If Repatha appears on Tier 5 with "PA" and "ST" notations, expect the plan to require both prior authorization and step therapy.

Build the documentation trail before the PA is submitted. Your prescriber should include lab results showing LDL-C on maximally tolerated statin plus ezetimibe, a clear statement of statin intolerance if applicable (specifying which statins were tried, at what doses, and what adverse effects occurred), and the specific FDA-approved indication that applies. The 2018 AHA/ACC cholesterol guideline recommends adding a PCSK9 inhibitor for patients with ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [12].

If the plan denies coverage, file a Coverage Determination Request. If that fails, request a first-level appeal (called a "redetermination") within 60 days. An Independent Review Entity (IRE) handles second-level appeals. The prescriber can also request an expedited determination if a delay would jeopardize the patient's health [13].

Amgen's Patient Assistance and Copay Programs

Amgen operates two distinct access programs for Repatha. The first is the Repatha Copay Card, which reduces out-of-pocket costs to as little as $5 per month for commercially insured patients. This card cannot be used by Medicare, Medicaid, or Tricare beneficiaries because federal anti-kickback statutes prohibit manufacturer copay assistance for federally funded programs [14].

The second is the Amgen Safety Net Foundation, a patient assistance program (PAP) that provides Repatha at no cost to patients who lack prescription coverage or whose coverage does not adequately pay for the drug and whose household income falls at or below 400% of the federal poverty level (FPL). In 2026 to 400% FPL is approximately $62,400 for a single-person household. Medicare Part D enrollees are eligible for the PAP if they meet income requirements and have no other coverage that would pay for the drug [15]. Applications require proof of income, a valid prescription, and a signed physician certification.

The NeedyMeds database, a nonprofit clearinghouse, lists additional independent charitable foundations that offer copay assistance for PCSK9 inhibitors. The HealthWell Foundation and the Patient Access Network (PAN) Foundation have historically run funds specific to hyperlipidemia, though these open and close depending on donations [16].

Clinical Evidence: Does Repatha Justify the Cost?

The primary cardiovascular outcomes trial for evolocumab, FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), enrolled 27,564 patients with established ASCVD and LDL-C of 70 mg/dL or higher on statin therapy. At a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) [17]. LDL-C dropped from a median of 92 mg/dL to 30 mg/dL.

A prespecified subanalysis of FOURIER showed that the benefit grew over time: patients treated beyond the first year had a 25% reduction in the key secondary endpoint of cardiovascular death, MI, or stroke [18]. Among patients with peripheral artery disease, the relative risk reduction for major adverse limb events was 42% [19].

Long-term safety data from the FOURIER open-label extension (FOURIER-OLE) followed 6,635 patients for a median of 5 years. No new safety signals appeared, and very low LDL-C levels (below 20 mg/dL) were not associated with increased adverse events [20]. The 2022 ACC Expert Consensus Decision Pathway reaffirmed that PCSK9 inhibitors are appropriate for high-risk ASCVD patients not at LDL-C goal despite maximally tolerated statin plus ezetimibe [21].

Repatha vs. Other LDL-Lowering Options on Medicare

Alirocumab (Praluent), the other approved PCSK9 inhibitor, carries a similar Part D tier placement and prior-authorization process. A network meta-analysis in the European Heart Journal found no significant difference in cardiovascular outcomes between evolocumab and alirocumab, though direct head-to-head trial data do not exist [22].

Inclisiran (Leqvio), a small interfering RNA (siRNA) targeting PCSK9 mRNA, received FDA approval in December 2021. It is dosed only twice yearly (after an initial dose and a 3-month booster), which may simplify adherence. The ORION-10 trial (N=1,561) demonstrated a 52% placebo-adjusted LDL-C reduction at day 510 [23]. From a Medicare access standpoint, inclisiran is administered by a healthcare provider and billed under Part B as a physician-administered drug, which means it avoids the Part D formulary process entirely. Patients pay the Part B coinsurance (typically 20% after the deductible) rather than navigating Part D prior authorization [24].

Bempedoic acid (Nexletol) is an oral ATP-citrate lyase inhibitor approved for ASCVD or HeFH. The CLEAR Outcomes trial (N=13,970) showed an 18% LDL-C reduction and a 13% reduction in major adverse cardiovascular events compared to placebo in statin-intolerant patients [25]. Because it is an oral small molecule with a lower list price, Part D plans sometimes require a trial of bempedoic acid before authorizing a PCSK9 inhibitor.

Prior Authorization Denial: What to Do Next

A denial is not the end. The CMS appeals process has five levels, and studies show that persistence pays. A 2023 Health Affairs analysis found that among Medicare Part D beneficiaries who appealed specialty-drug denials, 52% ultimately received coverage [26].

Your prescriber can submit a Letter of Medical Necessity citing the AHA/ACC guideline threshold: LDL-C at or above 70 mg/dL in very-high-risk ASCVD patients after maximally tolerated lipid-lowering therapy [12]. If statin intolerance is the basis, document at least two statin trials at different doses with specific myalgia or CK-elevation findings. The prescriber should reference the NLA (National Lipid Association) definition of statin intolerance, which requires symptoms that resolved after discontinuation and recurred upon rechallenge or trial of a second statin [27].

For patients with HoFH, denial rates are lower because the FDA label is narrow and the clinical need is unambiguous. Genetic testing results documenting LDLR, APOB, or PCSK9 mutations strengthen the case considerably.

Extra Help and Low-Income Subsidy (LIS)

Medicare's Extra Help program (also called the Low-Income Subsidy, or LIS) reduces Part D premiums, deductibles, and copays for beneficiaries with limited income and resources. In 2026, full LIS eligibility applies to individuals with income below 150% FPL (roughly $23,400) and limited assets. Partial LIS covers those between 150% and 200% FPL [28].

For a specialty-tier drug like Repatha, full LIS reduces the copay to $0 for generic or preferred drugs and a small fixed copay (currently $11.20 in the catastrophic phase) for brand-name drugs. Partial LIS enrollees pay a 15% coinsurance up to a reduced out-of-pocket threshold. Enrollees who qualify for both LIS and the Amgen Safety Net Foundation may pay nothing at all for their Repatha supply.

State Pharmaceutical Assistance Programs (SPAPs) in roughly 20 states provide additional premium or copay help for Part D enrollees. Programs vary widely; New York's EPIC program and Pennsylvania's PACE program are among the most generous for cardiovascular medications [29].

Biosimilars on the Horizon

No biosimilar to evolocumab has received FDA approval as of May 2026, but Amgen's key composition-of-matter patent (U.S. Patent 8,829,165) has been the subject of ongoing litigation. The Supreme Court ruled in 2023 that Amgen's broad genus claims covering antibodies that bind certain PCSK9 residues were not adequately enabled, invalidating those claims [30]. This decision may speed biosimilar development, though the regulatory and manufacturing complexity of monoclonal antibodies means a biosimilar launch is unlikely before 2028 at the earliest. When a biosimilar does arrive, CMS rules require Part D plans to place it on a tier no higher than the reference product, which could create meaningful competition and lower costs.